The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•31 March 2026•

1 min read

BioPorto Submits FDA Pre-Submission for Adult NGAL Diagnostic Program

FDA APPROVED container glowing with chemical molecules, an upward arrow, and "SUCCESS" text on an orange background with scientific diagrams and a DNA helix.

Key Facts

1BioPorto formally submitted its FDA pre-submission package for the U.S. Adult Urine NGAL program.

2The submission follows a positive EPACRA AKI Cut Off Analysis.

BioPorto A/S has officially submitted its pre-submission package to the U.S. Food and Drug Administration (FDA) for its adult urine NGAL program. This regulatory milestone follows a successful analysis of the EPACRA AKI study, which provided critical data for determining clinical cut-off levels. The diagnostic program focuses on identifying Acute Kidney Injury (AKI) through the company's proprietary NGAL testing technology. This submission represents a significant step forward in BioPorto's strategy to secure market clearance and expand its footprint in the United States. By advancing through the FDA's regulatory framework, the company demonstrates tangible progress in its clinical development pipeline. Investors view this move as a positive indicator of the company's ability to meet rigorous regulatory standards. The formal request sets the stage for further dialogue with the FDA regarding the commercialization of the NGAL test for adult patients.